Sabby Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Sabby Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-548	Closed	-$1.58M	–	258
2016 Q4	$1.58M	Buy	+548	New	+$14.5K	0.09%	120
2016 Q3	–	Sell	-495	Closed	-$1.61M	–	310
2016 Q2	$1.61M	Sell	495 -898	-64%	-$30.1K	0.08%	122
2016 Q1	$3.9M	Sell	1,393 -2,782	-67%	-$60.7K	0.19%	54
2015 Q4	$14.9M	Buy	4,175 +1,916	+85%	+$67.5K	0.82%	16
2015 Q3	$7.47M	Buy	2,259 +1,829	+425%	+$76.1K	0.31%	56
2015 Q2	$1.8M	Buy	+430	New	+$16.6K	0.07%	174
2015 Q1	–	Sell	-973	Closed	-$3.09K	–	287
2014 Q4	$3.09K	Buy	+973	New	+$27.6K	0.1%	96
2014 Q3	–	Sell	-960	Closed	-$2.17M	–	258
2014 Q2	$2.17M	Buy	960 +627	+188%	+$13.1K	0.09%	100
2014 Q1	$810K	Sell	333 -236	-41%	-$5.97K	0.05%	150
2013 Q4	$1.42M	Sell	569 -264	-32%	-$6.23K	0.09%	98
2013 Q3	$2.29M	Buy	+833	New	+$17.4K	0.15%	77

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sabby Management's ACAD Position: Q4 2020 in Review

Sabby Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2020, closing a stake of 99,921 shares — an estimated $4.12M sold.

Sabby Management first reported a position in ACAD in Q2 2013 and held it in 9 quarters. The position peaked at $14.6M in Q2 2013. 307 funds tracked by Wall St. Rank hold ACAD as of Q4 2020.

Sabby Management reported no remaining Acadia Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Sabby Management sold 99,921 Acadia Pharmaceuticals shares in Q4 2020, an estimated $4.12M.
Sabby Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Sabby Management's Acadia Pharmaceuticals position peaked at $14.6M in Q2 2013.
307 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.